Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Apr 1, 2018
Frequent source plasma donors are not at risk of iron depletion: the Ferritin Levels in Plasma Donor (FLIPD) study
Whole blood and red blood cell (RBC) donors are at risk of iron deficiency. Since Source plasma (SP) donors have RBCs returned during apheresis, risk of iron depletion appears low. However, SP donors can donate frequently and assessment of frequent donor iron status is needed.
All
Publication
https://pubmed.ncbi.nlm.nih.gov/29520799/
Apr 1, 2018
Frequent source plasma donors are not at risk of iron depletion: the Ferritin Levels in Plasma Donor (FLIPD) study
Whole blood and red blood cell (RBC) donors are at risk of iron deficiency. Since Source plasma (SP) donors have RBCs returned during apheresis, risk of iron depletion appears low. However, SP donors can donate frequently and assessment of frequent donor iron status is needed.
All
Publication
https://pubmed.ncbi.nlm.nih.gov/29520799/
Mar 16, 2018
PPTA Statement on “How Blood-Plasma Companies Target the Poorest Americans”
The article, “How Blood-Plasma Companies Target the Poorest Americans,” by H. Luke Shaefer and Analidis Ochoa, published in The Atlantic on March 15, was unfair to plasma donors as well as to individuals living with rare, genetic, and chronic diseases who rely on access to plasma protein therapies. Plasma donors are due our gratitude and respect, not sweeping negative characterizations.
All
PPTA statements
Mar 16, 2018
PPTA Statement on “How Blood-Plasma Companies Target the Poorest Americans”
The article, “How Blood-Plasma Companies Target the Poorest Americans,” by H. Luke Shaefer and Analidis Ochoa, published in The Atlantic on March 15, was unfair to plasma donors as well as to individuals living with rare, genetic, and chronic diseases who rely on access to plasma protein therapies. Plasma donors are due our gratitude and respect, not sweeping negative characterizations.
All
PPTA statements
Mar 1, 2018
The Source Spring 2018
Magazine of the plasma protein therapeutics industry - Spring 2018
All
The Source Magazine
https://drive.google.com/file/d/1-qXwMdB9LODxAprdsmlCnzrFkR3YPn9H/view?usp=sharing
Mar 1, 2018
The Source Spring 2018
Magazine of the plasma protein therapeutics industry - Spring 2018
All
The Source Magazine
https://drive.google.com/file/d/1-qXwMdB9LODxAprdsmlCnzrFkR3YPn9H/view?usp=sharing
Feb 1, 2018
Key Economic & Value Considerations in the US Market for PPTs
Plasma protein therapies (PPTs) are biologic medicines that provide critical health benefits, especially for patients with plasma protein deficiencies. Plasma protein deficiencies are a group of chronic, serious, and mostly rare conditions that occur when a person has deficient or functionally damaged proteins in plasma—the liquid portion of blood.
All
Publication
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/6454e9cb3bd98b1af1d2ac72_Key%20economic%20and%20value%20considerations%20in%20the%20U.S.%20market%20for%20plasma%20protein%20therapies.pdf
Feb 1, 2018
Key Economic & Value Considerations in the US Market for PPTs
Plasma protein therapies (PPTs) are biologic medicines that provide critical health benefits, especially for patients with plasma protein deficiencies. Plasma protein deficiencies are a group of chronic, serious, and mostly rare conditions that occur when a person has deficient or functionally damaged proteins in plasma—the liquid portion of blood.
All
Publication
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/6454e9cb3bd98b1af1d2ac72_Key%20economic%20and%20value%20considerations%20in%20the%20U.S.%20market%20for%20plasma%20protein%20therapies.pdf
No results found